Dossier
pubmed
review
Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting
Key claim: ASH 2025 updates highlight emerging MPN agents and regimens intended to address infrequent molecular remissions and treatment-limiting cytopenias of current therapies.
Abstract
Expert commentary review discussing emerging agents and regimens for MPN presented at ASH 2025, addressing limitations of current therapies including infrequent molecular remissions and treatment-limiting cytopenias.
Why this matters
ASH 2025 updates highlight emerging MPN agents and regimens intended to address infrequent molecular remissions and treatment-limiting cytopenias of current therapies.